Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy

Cancer Science

Volumn 108, Issue 10, 2017, Pages 1959-1966

  Ohno, Yosuke ^a,b   Toyoshima, Yujiro ^a,b   Yurino, Hideaki ^c   Monma, Norikazu ^d   Xiang, Huihui ^a   Sumida, Kentaro ^a   Kaneumi, Shun ^a   Terada, Satoshi ^a   Hashimoto, Shinichi ^c   Ikeo, Kazuho ^d   Homma, Shigenori ^b   Kawamura, Hideki ^b   Takahashi, Norihiko ^b   Taketomi, Akinobu ^b   Kitamura, Hidemitsu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF GENETICS   (Japan)

Author keywords

Cytotoxic T cells; dendritic cells; interferon ; interleukin 6; programmed death ligand 1

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 6; POLYINOSINIC POLYCYTIDYLIC ACID; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 3; ATEZOLIZUMAB; INTERLEUKIN-6, MOUSE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; HELPER CELL; IMMUNE STATUS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; COLONIC NEOPLASMS; DEFICIENCY; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DENDRITIC CELLS; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-6; MICE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85028561769     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13330     Document Type: Article

References (30)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.
2. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122–33.
3. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–65.
4. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265–77.
5. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39: 38–48.
6. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419–26.
7. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004; 305: 197–200.
8. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548–56.
9. Hirano T, Yasukawa K, Harada H et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73–6.
10. Knpfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patient—A summary of published results. Int J Colorectal Dis 2010; 25: 135–40.
11. Makuuchi Y, Honda K, Osaka Y et al. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci 2013; 104: 1045–51.
12. Hazama S, Takenouchi H, Tsunedomi R et al. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Res 2014; 34: 4201–5.
13. Kitamura H, Kamon H, Sawa SI et al. IL-6-STAT3 controls intracellular MHC class II αβ dimer level through cathepsin S activity in dendritic cells. Immunity 2005; 23: 491–502.
14. Park SJ, Nakagawa T, Kitamura H et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173: 3844–54.
15. Sumida K, Wakita D, Narita Y et al. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol 2012; 42: 2060–72.
16. Narita Y, Kitamura H, Wakita D et al. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J Immunol 2013; 190: 812–20.
17. Tsukamoto H, Nishikata R, Senju S et al. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol Res 2013; 1: 64–76.
18. Tsukamoto H, Senju S, Matsumura K et al. IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age. Nat Commun 2015; 6: 6702.
19. Tsukamoto H, Fujieda K, Hirayama M et al. Soluble IL-6R expressed by myeloid cells reduces tumor-specific Th1 differentiation and drives tumor progression. Cancer Res 2017; 77: 2279–91.
20. Ohno Y, Kitamura H, Takahashi N et al. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells. Cancer Immunol Immunother 2016; 65: 193–204.
21. Hu Y, Cong X, Chen L et al. Synergy of TLR3 and 7 ligands significantly enhances function of DCs to present inactivated PRRSV antigen through TRIF/MyD88-NF-κB signaling pathway. Sci Rep 2016; 6: 23977.
22. Morinobu A, Gadina M, Strober W et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci USA 2002; 99: 12281–6.
23. Hsich CS, Macatonia SE, Tripp CS et al. Development of TH1 CD4+ T cells through IL-12 produced by listeria-induced macrophage. Science 1993; 260: 547–9.
24. Kalinski P, Hilkens CM, Snijders A et al. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997; 159: 28–35.
25. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190: 617–27.
26. Bellucci R, Martin A, Bommarito D et al. Interferon-g-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 2015; 4: e1008824.
27. Kharma B, Baba T, Matsumura N et al. STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res 2014; 74: 6519–30.
28. Abiko K, Matsumura N, Hamanishi J et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015; 112: 1501–9.
29. Azuma M, Takeda Y, Nakajima H et al. Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology 2016; 5: e1188244.
30. Dijkgraaf EM, Santegoets SJ, Reyners AK et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. Ann Oncol 2015; 26: 2141–9.